



Multiple Sclerosis: A Comprehensive Review of Pathophysiology, Clinical Manifestations, Diagnosis, Treatment, and Future Perspectives

Mozan Ali Abdalla Mohamed^{1,2}, Rafa Omer Mohamed Elkhailifa^{1,2}, Aba Aiad Abdelgadir Sheikh Edris^{1,2}, Enas Eltayeb Ezzeldeen Eltayeb^{1,2*}, Alaa Abdelwahab Ibrahim Younis^{1,2}

¹Faculty of Pharmacy, Arab Academy for Science, Technology and Maritime Transport (AASTMT), El Alamein 51718, Egypt.

²School of Pharmacy, Ahfad University for women (AUW), Khartoum, Sudan.

*Corresponding author: Enas Eltayeb Ezzeldeen Eltayeb, email: enaseltayeb502@gmail.com

All authors contributed equally.

Abstract

Multiple Sclerosis (MS) is a chronic autoimmune disorder of the central nervous system with an increasing global prevalence. Its etiology involves a complex interaction between genetic susceptibility and environmental factors. This review examines the pathophysiology of MS, focusing on the immune-mediated demyelination and neurodegeneration that drive disease progression. We summarize the diverse clinical manifestations of the disease, from common sensory-motor deficits to less typical presentations. Diagnostic approaches are discussed, including the application of the 2017 McDonald Criteria and the roles of neuroimaging, cerebrospinal fluid analysis, and evoked potentials. We also highlight the emerging use of artificial intelligence in improving diagnostic accuracy and prognosis. The current landscape of disease-modifying therapies is outlined, covering established treatments for relapsing MS and addressing the unmet need for effective therapies for progressive forms of the disease. Finally, we discuss future perspectives in MS treatment, including stem cell therapies and novel biomedical engineering strategies aimed at promoting remyelination. This review synthesizes current knowledge to provide a comprehensive overview of the path from diagnosis to emerging therapeutic frontiers in Multiple Sclerosis.

Keywords: Multiple Sclerosis, Autoimmune Disease, Disease-Modifying Therapies, Artificial Intelligence, Stem Cells.

1. Introduction

Autoimmune diseases (ADs) represent a diverse group of conditions where the body's immune system continually attacks its own cells and tissues, a phenomenon termed autoimmunity. This broad category encompasses over 100 distinct diseases, including several examples such as type 1 diabetes mellitus, rheumatoid arthritis, systemic lupus erythematosus, and multiple sclerosis [1-5]. ADs are typically categorized as either organ-specific (OS), where the immune response is directed against antigens within a single organ, or non-organ-specific (NOS), involving systemic immune attack across multiple systems. Multiple sclerosis (MS) is an example of an NOS autoimmune disease, specifically targeting the central nervous system (CNS) [6-9].

Multiple sclerosis is a chronic, demyelinating, and inflammatory disease primarily affecting the brain and spinal cord [16-18]. Demyelination, the hallmark of MS, involves the inappropriate immune-mediated destruction of myelin, the fatty sheath that insulates nerve fibers. This damage disrupts efficient neuronal communication, leading to a wide spectrum of sensory, motor, and cognitive impairments [19]. Globally, MS is recognized as the most prevalent chronic inflammatory disease of the CNS, affecting over 2.8 million individuals worldwide [10]. The disease exhibits a notable sex disparity, with the majority of diagnoses occurring in women [11]. While the precise reasons for this are not fully understood, contributing factors may include sex-specific epigenetic modifications, significant hormonal fluctuations during puberty, and environmental influences such as varying sun exposure [12].

The etiology of MS is complex, arising from intricate interactions between genetic predisposition and environmental exposures [13]. Key environmental factors contributing to MS risk include sunlight exposure, vitamin D levels, dietary habits, early-life

obesity, smoking, and infections with agents like Epstein-Barr virus (EBV), human herpesvirus-6 (HHV-6), and human endogenous retroviruses [14, 15]. These exposures may contribute to the observed increase in MS incidence year by year. Despite the global prevalence of MS, the exact primary risk factors remain incompletely understood. Furthermore, the absence of a definitive cure underscores the urgent and ongoing need for continued research to discover more advanced and effective treatment options. MS represents a serious and potentially disabling autoimmune disorder that profoundly impacts the quality of life of affected individuals, characterized by its chronic nature and progressive neurological symptoms.

This comprehensive review aims to provide a detailed overview of multiple sclerosis, focusing on five critical domains essential for understanding and managing the disease: its pathophysiology, clinical manifestations, diagnostic approaches, current treatment options, and future perspectives. By systematically examining these areas, we highlight the multifaceted complexity of MS and the persistent global efforts dedicated to improving outcomes for those living with this challenging condition.

2. Pathophysiology of Multiple Sclerosis

Multiple sclerosis is characterized by a progressive neuropathological process involving inflammation and nerve damage within the CNS, which can ultimately lead to permanent neurological disability [20]. The disease's impact can be profound, with symptoms such as tremors significantly affecting daily life, potentially leading to early retirement or unemployment [21]. Timely recognition of MS as a cause of new tremor symptoms is crucial to avoid delays in diagnosis and the initiation of appropriate therapy [21].

The pathogenesis of MS involves a complex interplay of immune cells and glial cells within the CNS. While interactions between astrocytes and microglia can exacerbate neuroinflammation in various brain diseases, they also play a crucial role in mitigating CNS damage. For instance, microglia-derived Interleukin-10 (IL-10) can induce astrocytes to release transforming growth factor beta (TGF- β), which in turn helps suppress microglial inflammation [22]. A central event in MS is the aberrant activation of T lymphocytes, which become self-reactive upon encountering an unknown autoantigen presented by major histocompatibility complex (MHC) class II molecules [23, 24]. These autoreactive T cells then migrate to peripheral lymphoid organs, where they proliferate. Following activation by sphingosine-1-phosphate (S1P), these activated T cells circulate in the bloodstream. Upon stimulation, they adhere to overexpressed adhesion molecules on the endothelial lining of blood vessels and secrete Matrix Metalloproteinases (MMPs), enzymes that degrade

components of the extracellular matrix. This enzymatic activity facilitates the breach of the blood-brain barrier (BBB), allowing immune cells to infiltrate the CNS [24]. Within the CNS, these infiltrating immune cells contribute to the pathological process by producing a diverse array of cytokines, including both pro-inflammatory and anti-inflammatory mediators [25]. While MS commonly manifests in individuals aged 20 to 40 years, it can develop at any age. The average age of onset for relapsing-remitting MS (RRMS) is typically 25 to 29 years, whereas primary progressive MS (PPMS) generally presents later, between 39 to 41 years [26]. Certain infections, particularly EBV, are thought to influence disease onset [27].

The spatial distribution of spinal cord lesions varies across MS subtypes. The dorsal column is frequently affected in all forms, while the lateral funiculi are more commonly impacted in primary and secondary progressive MS compared to the relapsing-remitting form [28]. Cervical spinal cord atrophy serves as a significant indicator of disease progression, often predicting the transition to secondary progressive MS (SPMS) even in the absence of overt clinical relapses or other active disease symptoms [29].

Experimental autoimmune encephalomyelitis (EAE) is the most widely utilized animal model for MS. This model is characterized by an adaptive immune response where myelin-reactive T cells infiltrate the CNS, leading to autoimmune demyelination and axonal destruction [30]. The progression of MS pathophysiology, from immune activation to chronic axonal damage, is schematically represented in Figure 1.




Figure 1. Progression of Multiple Sclerosis Pathophysiology.

The clinical presentation of MS can be highly variable due to individual patient factors, including age, sex, genetic background, environmental exposures, and disease duration [31]. Furthermore, the senescence of different CNS cell subtypes, which can be accelerated by the disease process itself, may influence disease progression. In senescent microglia, reduced phagocytic activity can lead to persistent inflammatory cytokine release and hinder remyelination. Similarly, senescent astrocytes can impair synaptic plasticity, disrupt BBB function, and disturb the metabolic stability of adjacent neurons [32]. Cytokines and chemokines found in the cerebrospinal fluid (CSF) primarily originate from

meningeal infiltrates. Their distribution correlates with the presence and size of cortical lesions, the degree of neurodegeneration in the cortex, and the release of neurofilament light chain (NfL) protein, a recognized biomarker of neurodegeneration [33].

3. Clinical Manifestations of MS

Multiple sclerosis presents with a broad array of symptoms reflecting the widespread nature of CNS lesions. The diversity and intensity of these symptoms are directly influenced by the quantity, specific location, and severity of tissue damage [34]. Interestingly, clinical symptoms may not always correlate directly with MRI evidence of active plaques, highlighting the role of repair mechanisms and brain plasticity in tissue injury and recovery processes [34].

Typical clinical manifestations frequently noted in patient history include:

- Visual problems: Common symptoms involve visual loss (either monocular or homonymous), diplopia (double vision), pain with eye movement, and signs characteristic of optic neuritis [34].
- Vestibular symptoms: Imbalanced gait and vertigo are also frequently observed [34].
- Bulbar dysfunction: Dysarthria (slurred speech) and dysphagia (difficulty swallowing) may occur, indicating involvement of the lower cranial nerves [34].
- Motor symptoms: Prominent motor deficits often include debilitating fatigue, tremors, spasticity, and varying degrees of weakness, such as hemiparesis (weakness on one side of the body), monoparesis (weakness in one limb), or paraparesis (weakness in both legs) [35-37].
- Sensory disturbances: These are typical and may present as a band-like sensation around the chest or abdomen (MS hug), paresthesia (tingling or prickling sensation), dysesthesias (unpleasant abnormal sensations), or numbness [36].
- Autonomic dysfunction: Commonly affects the digestive and urinary systems, leading to symptoms like gastroesophageal reflux, diarrhea, constipation, urinary urgency, retention, or incontinence [35, 36].
- Cognitive issues: Difficulties with concentration, memory impairment, and problems with executive functions are frequently reported [35].
- Psychiatric manifestations: Depression and anxiety often coexist with MS and can significantly impact quality of life [35].
- Brainstem involvement: Can result in symptoms such as diplopia, oscillopsia (illusory movement of visual field), facial muscle weakness, and reduced facial sensation [35]. The primary clinical manifestations of MS are further illustrated in Figure 2.




Figure 2. The main clinical manifestations of multiple sclerosis.

4. Atypical Features Warranting Further Evaluation in Suspected MS

Certain clinical features are considered atypical for MS and should prompt careful consideration of alternative diagnoses [36, 38]. These include:

- The presence of seizures.
- A steadily progressive course without relapses from onset (unless primary progressive MS is being considered, but typically atypical for typical RRMS).
- Symptoms that develop abruptly within minutes.
- Disease onset before the age of 10 or after 50.
- Movement abnormalities such as rigidity or sustained dystonia.
- Cortical signs like apraxia, alexia, aphasia, or neglect.
- Early-onset dementia [36].

Most MS patients experience a RRMS, characterized by episodic neurological exacerbations (relapses) followed by periods of partial or complete recovery. During the recovery phases, the disease remains clinically stable [36]. Relapses in RRMS typically involve the gradual development of new or recurrent neurological symptoms over several days to weeks, usually lasting between 24 and 48 hours, and often showing partial or complete resolution. However, with repeated relapses over time, patients may accumulate residual neurological deficits, leading to long-term disability [37]. This progression often becomes more apparent after 10 to 15 years of disease onset, at which point many patients transition to a secondary progressive course (SPMS), marked by a steady worsening of symptoms with or without ongoing relapses. The neurological manifestations in RRMS vary widely in terms of severity and the degree of recovery following each episode [37].

Other atypical features that warrant further evaluation in suspected MS include [38]:

- Seizures and Sleep Disorders: Such as obstructive sleep apnea, nocturia, insomnia, and restless legs syndrome [39].
- Transient or Paroxysmal Neurological Events: These are brief, often lasting only seconds, and can occur with variable frequency. They include:
 - Abnormal or unexplained sensations spreading across the body.
 - Brainstem-related manifestations like blurred vision, diplopia, dysarthria, and vertigo.

- Motor disturbances such as transient inhibition of motor function, tonic spasms, or ataxia.
- Rarely, gustatory symptoms (taste hallucinations or altered taste perception) or thermoregulatory issues (hypothermia or hyperthermia) [39].
- Visual Disturbances: May present as the Pulfrich phenomenon (arising from a mismatch in visual acuity between the eyes, causing objects moving in a straight line to appear to follow an elliptical path). These visual abnormalities can lead to practical difficulties in daily activities [39].
- Distinctive but Uncommon Symptoms:
- The "useless hand of Oppenheim," where the patient experiences a sudden loss of function in the hand.
- The Lhermitte phenomenon, particularly when triggered by less typical actions such as limb movements, neck extension, or coughing [39].

5. Diagnosis of MS

The diagnosis of MS relies on an integrated assessment of clinical presentation, neuroimaging findings, and laboratory results [40]. While no single test is definitively diagnostic [41], various diagnostic criteria have been developed to synthesize clinical observations with supportive ancillary data, facilitating accurate disease identification [42]. The most widely utilized diagnostic framework is the McDonald Criteria.

I. The 2017 McDonald Criteria: Originally introduced in 2001 and subsequently revised in 2005, the McDonald Criteria underwent its most recent update in 2017, as presented in Table 1 [40, 42]. The 2017 revision refined diagnostic principles by eliminating the distinction between symptomatic and asymptomatic lesions and by re-categorizing juxtacortical involvement, merging cortical and juxtacortical lesions. This broadened the scope of lesion localization within the central nervous system. The fundamental principle of these criteria is the demonstration of dissemination in time (DIT) and dissemination in space (DIS), evidenced through clinical manifestations and/or magnetic resonance imaging (MRI) findings [40].

II. Magnetic Resonance Imaging (MRI): The advent of MRI in the early 1980s revolutionized the diagnostic and therapeutic landscape of MS, providing unparalleled in vivo visualization of lesion activity and disease burden. Through continuous technological advancements over the subsequent decades, MRI has evolved into the most essential paraclinical modality for both the initial diagnosis and ongoing monitoring of MS [43]. MRI plays a pivotal role in MS diagnosis, with current International Panel on MS Diagnosis criteria allowing for disease confirmation based on findings from a single time-point MRI scan [42].

MRI techniques used in the evaluation of MS are broadly classified into two main categories: conventional and advanced.

Table 1. 2017 McDonald Criteria for Diagnosis of Relapsing-Remitting MS (RRMS)

Number of Clinical Attacks	Number of Lesions with Clinical Evidence	Additional Evidence Required for MS Diagnosis
2 or more	Lesions in 2 or more CNS locations	No additional information needed. Diagnosis confirmed.
2 or more	Lesion in only 1 CNS location	No additional information needed. Diagnosis confirmed.
2 or more	No MRI lesions, only one CNS site involved	Need proof of dissemination in space (DIS) via another clinical attack affecting a different CNS site or by MRI evidence.
1	Lesions in 2 or more CNS locations	Need proof of dissemination in time (DIT) via a second attack, MRI findings of new lesion(s), or positive CSF-specific oligoclonal bands.
1	Lesion in only 1 CNS location	Must demonstrate both: DIS (via another attack or MRI showing different CNS region), and DIT (via new clinical attack, MRI, or CSF oligoclonal bands).

- Conventional MRI encompasses widely accessible, well-established, and highly standardized imaging protocols, first integrated into the diagnostic framework with the original International Panel guidelines [44]. These protocols typically include T2-weighted, fluid-attenuated inversion recovery (FLAIR), short-tau inversion recovery (STIR), and T1-weighted sequences acquired before and after gadolinium contrast administration. These are usually performed at magnetic field strengths of 1.5 Tesla in both the brain and spinal cord and remain central to routine clinical assessment and decision-making in MS.

- Advanced MRI techniques, particularly those conducted at higher magnetic field strengths such as 3T and 7T, offer superior signal-to-noise ratios and markedly improved spatial resolution (reaching scales as fine as 100 µm). However, these benefits are accompanied by limitations including greater susceptibility to imaging artifacts, limited protocol standardization across institutions, and higher operational costs [45]. A variety of specialized MRI pulse sequences, such as magnetization transfer imaging (MT), magnetic resonance spectroscopy (MRS), diffusion-weighted imaging, and the use of emerging

contrast agents, have also been employed to enhance diagnostic specificity in MS [46].

III. Spinal Fluid Analysis: The primary advantage of utilizing CSF rather than blood for biomarker measurement in MS is its superior ability to more precisely reflect the inflammatory profile of the CNS [47]. CSF biomarkers offer greater sensitivity than clinical evaluations or MRI scans, particularly when assessing low-grade disease activity in MS. In certain patients whose disease was considered inactive based on clinical scales and/or MRI, levels of CSF NfL and the immunoglobulin G (IgG) index were notably elevated [48].

The IgG index is a ratio that compares the levels of IgG to albumin in the CSF with those in the serum [49]. A ratio greater than 0.7 typically supports a diagnosis of MS. While analyzing CSF for inflammatory markers, such as oligoclonal bands (OCBs) and the IgG index, is useful in diagnosis, these markers are not optimal for predicting relapse and disease progression [50]. The sensitivity of oligoclonal bands can be limited due to difficulties in determining the number of bands present, and their specificity is low as any condition causing chronic CNS inflammation can lead to their increase [50]. However, several studies indicate that IgM-type oligoclonal bands are linked to heightened disease activity in MS, increased retinal axonal loss, reduced retinal nerve fiber layer thickness, and more aggressive disease progression during the early stages of RRMS [49, 51, 52, 53, 54].

IV. Evoked Potentials: Evoked potentials (EPs), including visual evoked potentials (VEPs), somatosensory evoked potentials (SSEPs), and brainstem auditory evoked responses (BAERs), are non-invasive methods used to evaluate neural conduction across various sensory pathways [55]. These tests involve stimulating the respective sensory system, with a scalp electrode placed over the corresponding cortical area to measure latency and amplitude. Prolonged latency is indicative of demyelination-induced damage, making EPs a valuable tool for diagnosing MS and assessing specific neural pathways [55]. Additionally, EPs have a proposed role in predicting MS prognosis and monitoring treatment response, though their widespread clinical application in this context is still developing [56].

V. Kappa Free Light Chain (KFLC): Kappa free light chains (KFLC) are generated during antibody synthesis by plasma cells [53]. CSF Kappa free light chains have been suggested as an additional diagnostic marker for MS, offering similar sensitivity and specificity to oligoclonal bands [57]. Unlike OCBs, KFLC measurements do not require a paired serum sample and provide rapid, machine-operated results, eliminating the need for visual assessment [57]. Specifically, KFLC levels have been found to be elevated in both the CSF and serum of patients with MS [58], and have been

associated with future disability progression [59]. Higher CSF levels of KFLC in patients with clinically isolated syndrome (CIS) have also been linked to an earlier conversion to clinically defined MS [60].

VI. The Contribution of AI in Diagnosis: Recent advancements in technology and the increasing availability of large-scale data have facilitated the integration of artificial intelligence (AI) algorithms into the diagnostic work-up of MS [61]. Convolutional neural networks (CNNs), a form of deep learning (DL) capable of automatically extracting relevant features, have successfully distinguished between MS patients and healthy controls (HC) with high accuracy (ranging from 70.2% to 98.8%) based on various MRI sequences, including T2-weighted [62, 63], FLAIR [64], and susceptibility-weighted MRI [65]. Machine learning (ML) algorithms, designed to learn from predefined data features to make decisions or predictions, have also shown promising results. When trained on quantitative MRI data (e.g., from diffusion-weighted [66– 69] and resting-state functional MRI sequences [69, 70]), these algorithms can accurately identify MS patients, achieving classification accuracies ranging from 83.7% to 90.0% [71]. This highlights AI's potential to identify subtle patterns and relationships that support diagnostic and prognostic assessments [66–68].

6. Current Treatment and Future Perspectives

Historically, conventional approaches to MS treatment focused on preventing and managing acute attacks and modifying lifestyle, often employing broad immunosuppression to reduce CNS deterioration and diminish disability, as illustrated in Figure 3. Despite some success, these treatments frequently presented numerous, and at times severe, potential side effects [20]. Furthermore, these traditional therapies largely failed to address the underlying pathology of the disease, particularly the inability to promote remyelination and effectively treat progressive MS. However, significant breakthroughs in stem cell therapy and immune modulation, combined with novel biomedical engineering approaches, have opened new avenues for therapy. These emerging therapeutic strategies are increasingly patient-tailored, aiming to remyelinate specific structures through regenerative approaches, thereby potentially reversing the course of the disease. Several promising therapeutic approaches have been devised over recent years, each demonstrating encouraging outcomes in preclinical and clinical trials [73].

Summary of Disease-Modifying Therapies (DMTs): The growth in the discovery of early disease-modifying treatments (DMTs) has paralleled advances in understanding MS pathology. Earlier preclinical work emphasized the proliferation of autoreactive cells, particularly T cells, in peripheral lymphoid organs, their subsequent migration, and residence in the CNS, leading to focal pathology. However, clinical trials focused

exclusively on T-cell treatments have shown limited success for relapsing MS (RMS) patient groups (Table 2) [73].

Disease Category	Treatment Recommendation		
Clinically Isolated Syndrome favorable characteristics and no residual disability Relapsing MS no or minimal disability and inactive MRI scans	Option One fingolimod OR dimethyl fumarate	Option Two glatiramer acetate OR interferon beta OR teriflunomide	Option Three no DMT
Clinically Isolated Syndrome unfavorable characteristics Relapsing MS at least one relapse in prior two years and/or an active MRI	Option One ocrelizumab OR natalizumab* *only if JCv negative	Option Two fingolimod OR dimethyl fumarate	
Active Secondary Progressive MS	Option One siponimod	Option Two ocrelizumab	
Primary Progressive MS	Option One ocrelizumab		

Figure 3. Treatment Recommendations by Disease Category

Table 2. Types of Disease-Modifying Therapies (DMTs)

Aspect	Injectable DMTs	Oral DMTs	Monoclonal Antibody
Development	1 st generation therapies; advancing with regenerative approaches like stem cells [74].	Developed for better patient compliance via oral dosing [72, 76].	Advanced immuno-engineered therapies following injectables and orals [75].
Efficacy	Promising results in reversing disease in trials [74].	Reduced relapse rates by 36–58% over 2 years.	Highly effective in lowering relapse rates in RMS [75].
Mechanism	Immune modulation; newer focus on regeneration	Mainly act through S1P receptor modulation	Block immune cell migration into the CNS (e.g., Natalizumab)
Key Feature	Personalized regenerative potential [74].	Improved convenience and adherence [72, 76].	Targeted, high-potency therapies; first-in-class Natalizumab [75].

Non-Conventional Overview of Stem Cells: Table 3 showing the different applications of neural stem cells (NSCs) for MS treatment stems from an enhanced understanding of CNS repair mechanisms. Major CNS repair mechanisms can be broadly categorized into inflammatory and plasticity-dependent pathways [78]. Activation of the pro-inflammatory pathway can lead to a functional reorientation in the CNS, where immune components favor tissue repair through neurotrophic support.

Remarkable advances have occurred in the treatment of MS due to a deeper understanding of its pathogenesis and disease course. Highly effective treatments have achieved near-complete suppression of relapsing disease and focal brain inflammation. However, addressing disease progression remains an unmet need, as current therapies offer incomplete protection against the neurodegenerative component of MS. Although natural history cohorts indicate that the long-term disease course has been significantly improved since the advent of modern treatments, further clinical and real-world studies are essential to provide long-term efficacy and safety data for these therapies. Additional studies on the value of highly effective drugs for early treatment and the identification of patients who derive maximum benefit will also be crucial as we strive towards delivering evidence-based and personalized management and treatment strategies for MS.

7. Conclusion

Multiple sclerosis is a complex and lifelong neurological condition that significantly affects patients' physical, psychological, and social well-being. This review highlights the importance of early diagnosis and continuous treatment as essential strategies for managing symptoms and improving quality of life. Beyond pharmacological interventions, psychosocial support—such as psychological counseling and community engagement—plays a critical role in comprehensive care. A holistic, patient-centered approach that integrates medical and emotional support is essential for addressing the multifaceted challenges faced by individuals with MS. As therapeutic innovations continue to emerge, sustained public awareness, personalized care, and empathy remain fundamental to empowering patients to live with dignity, resilience, and hope.

Conflict of Interest

The authors declare that there is no conflict of interest regarding the publication of this paper.

Acknowledgement

The authors gratefully acknowledge the support and guidance provided by Dr. Yousra A. El-Maradny, which significantly contributed to the successful completion of this review article.

Table 3. Neural Stem Cells (NSCs) Bioengineering in MS

Aspect	Neural Stem Cells (NSCs)	Induced Pluripotent Stem Cells (iPSCs)	Biomaterials for NSCs & iPSCs	Nano-Biomedical Engineering for Systemic Delivery
Key Role in MS	Show regenerative potential by differentiating into neuronal and glial cells; capable of crossing the blood–brain barrier [77].	Enable patient-specific regeneration; reprogrammed from somatic cells using key transcription factors (e.g., KLF4, NANOG) [78].	Support survival and maturation of transplanted stem cells in hostile CNS environments [79–84].	Enhance targeting, survival, and tracking of IV-delivered stem cells using magnetic nanoparticles [85, 86].
Delivery Method	Direct CNS implantation.	Reprogrammed cells prepared for CNS application.	Typically, via spinal cord injection with supportive matrices.	Intravenous delivery guided by external magnetic fields.
Limitations & Advances	Still in preclinical stages; both direct and indirect regeneration reported [77].	Bypasses ethical issues of embryonic stem cells; ongoing optimization needed [78].	Hydrogels and ECM scaffolds improve integration in inflammatory tissues [79–84].	Nanotech improves engraftment and migratory control; systemic fate remains under study [85, 86].

References

1. Furman D, Campisi J, Verdin E, Carrera-Bastos P, Targ S, Franceschi C, et al. Chronic Inflammation in the Etiology of Disease Across the Life Span. *Nat Med*. 2019;25(12):1822-32. <https://doi.org/10.1038/s41591-019-0675-0>
2. Handel AE, Handunnetthi L, Ebers GC, Ramagopalan SV. Type 1 Diabetes Mellitus and Multiple Sclerosis: Common Etiological Features. *Nat Rev Endocrinol*. 2009;5(12):655-64. <https://doi.org/10.1038/nrendo.2009.216>
3. Tettey P, Simpson S, Taylor BV, van der Mei IAF. The Co-Occurrence of Multiple Sclerosis and Type 1 Diabetes: Shared Aetiologic Features and Clinical Implication for MS Aetiology. *J Neurol Sci*. 2015;348(1-2):126-31. <https://doi.org/10.1016/j.jns.2014.11.019>
4. Bieber K, Hundt JE, Yu X, Ehlers M, Petersen F, Karsten CM, et al. Autoimmune pre-disease. *Autoimmun Rev*. 2023;22:103236. <https://doi.org/10.1016/j.autrev.2022.103236>
5. Wang L, Wang FS, Gershwin ME. Human autoimmune diseases: A comprehensive update. *J Intern Med*. 2015;278:369-95. <https://doi.org/10.1111/joim.12395>
6. Moroncini G, Calogera G, Benfaremo D, Gabrielli A. Biologics in Inflammatory Immune-mediated Systemic Diseases. *Curr Pharm Biotechnol*. 2017;18:1008-16. <https://doi.org/10.2174/1389201019666171226152448>
7. Ceccarelli F, Govoni M, Piga M, Cassone G, Cantatore FP, Olivieri G, et al. Arthritis in Systemic Lupus Erythematosus: From 2022 International GISEA/OEG Symposium. *J Clin Med*. 2022;11:6016. <https://doi.org/10.3390/jcm11206016>
8. Bach JF. The hygiene hypothesis in autoimmunity: The role of pathogens and commensals. *Nat Rev Immunol*. 2018;18:105-20. <https://doi.org/10.1038/nri.2017.111>
9. McLeod DS, Cooper DS. The incidence and prevalence of thyroid autoimmunity. *Endocrine*. 2012;42:252-65. <https://doi.org/10.1007/s12020-012-9703-2>
10. Walton C, King R, Rechtman L, Kaye W, Leray E, Marrie RA, Robertson N, La Rocca N, Uitdehaag B, van Der Mei I, Wallin M. Rising prevalence of multiple sclerosis worldwide: Insights from the Atlas of MS. *Multiple Sclerosis Journal*. 2020 Dec;26(14):1816-21. <https://doi.org/10.1177/1352458520970841>
11. Hagan KA, Munger KL, Ascherio A, Grodstein F. Epidemiology of Major Neurodegenerative Diseases in Women: Contribution of the Nurses' Health Study. *Am J Public Health*. 2016;106(9):1650-5. <https://doi.org/10.2105/AJPH.2016.303324>
12. Ascherio A, Munger KL, Lunemann JD. The Initiation and Prevention of Multiple Sclerosis. *Nat Rev Neurol*. 2012;8(11):602-12. <https://doi.org/10.1038/nrneurol.2012.198>
13. Compston A, Coles A. Multiple sclerosis. *Lancet*. 2008;372(9648):1502-17. [https://doi.org/10.1016/S0140-6736\(08\)61620-7](https://doi.org/10.1016/S0140-6736(08)61620-7)
14. GBD 2015 Neurological Disorders Collaborator Group. Global, regional, and national burden of neurological disorders during 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. *Lancet Neurol*. 2017. [http://dx.doi.org/10.1016/S1474-4422\(17\)30299-5](http://dx.doi.org/10.1016/S1474-4422(17)30299-5)
15. Mey GM, Mahajan KR, DeSilva TM. Neurodegeneration in multiple sclerosis. *WIREs mechanisms of disease*. 2023 Jan;15(1):e1583. <https://doi.org/10.1002/wsbm.1583>

16. Orton S-M, Herrera BM, Yee IM, et al. Sex ratio of multiple sclerosis in Canada: a longitudinal study. *Lancet Neurol.* 2006;5:932-6. [https://doi.org/10.1016/S1474-4422\(06\)70581-6](https://doi.org/10.1016/S1474-4422(06)70581-6)
17. Krysko KM, Graves JS, Dobson R, Altintas A, Amato MP, Bernard J, et al. Sex effects across the lifespan in women with multiple sclerosis. *Ther Adv Neurol Disord.* 2020;13:1756286420936166. <https://doi.org/10.1177/1756286420936166>
18. Olsson T, Barcellos LF, Alfredsson L. Interactions between genetic, lifestyle and environmental risk factors for multiple sclerosis. *Nat Rev Neurol.* 2017;13:25-36. <https://doi.org/10.1038/nrneurol.2016.187>
19. Marrie RA. Environmental risk factors in multiple sclerosis aetiology. *Lancet Neurol.* 2004;3:709-18. [https://doi.org/10.1016/S1474-4422\(04\)00933-0](https://doi.org/10.1016/S1474-4422(04)00933-0)
20. Bar-Or A, Pender MP, Khanna R, Steinman L, Hartung HP, Maniar T, et al. Epstein-Barr virus in multiple sclerosis: theory and emerging immunotherapies. *Trends Mol Med.* 2020;26:296-310. <https://doi.org/10.1016/j.molmed.2019.11.003>
21. Hauser SL, Waubant E, Arnold DL, Vollmer T, Antel J, Fox RJ, et al. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. *N Engl J Med.* 2008;358(7):676-88. <https://doi.org/10.1056/NEJMoa0706383>
22. Makhoul K, Ahdab R, Riachi N, Chalah MA, Ayache SS. Tremor in Multiple Sclerosis-An Overview and Future Perspectives. *Brain Sci.* 2020;10(10). <https://doi.org/10.3390/brainsci10100722>
23. Norden DM, Fenn AM, Dugan A, Godbout JP. TGF β produced by IL-10 redirected astrocytes attenuates microglial activation. *Glia.* 2014;62:881-95. <https://doi.org/10.1002/glia.22647>
24. Al-Samydai M, Al-kholaifeh A, Al-Samydai A. The impact of social media in improving patient's mental image towards healthcare provided by private hospitals' in Amman/Jordan. *Indian J Public Health Res Dev.* 2019;10:491. <https://doi.org/10.5958/0976-5506.2019.00339.5>
25. Martin R, Sospedra M, Eiermann T, et al. Multiple sclerosis: doubling down on MHC. *Trends Genet.* 2021;37:784-97. <https://doi.org/10.1016/j.tig.2021.04.012>
26. Pushpalatha P, Monaghan KL, Milne SM, Wan ECK. Cytokine Signaling in Multiple Sclerosis and Its Therapeutic Applications. *Med Sci (Basel).* 2017;5(4):23. <https://doi.org/10.3390/medsci5040023>
27. Zurawski J, Stankiewicz J. Corrigendum to Multiple Sclerosis Re-Examined: Essential and Emerging Clinical Concepts. *Am J Med.* 2018;131(12):1528. <https://doi.org/10.1016/j.amjmed.2018.08.002>
28. Guan Y, Jakimovski D, Ramanathan M, Weinstock-Guttman B, Zivadinov R. The role of Epstein-Barr virus in multiple sclerosis: from molecular pathophysiology to in vivo imaging. *Neural Regen Res.* 2019;14(3):373-86. <https://doi.org/10.4103/1673-5374.245462>
29. Eden D, Gros C, Badji A. Spatial distribution of multiple sclerosis lesions in the cervical spinal cord. *Brain.* 2019;142:633-46. <https://doi.org/10.1093/brain/awy352>
30. Bischof A, Papinutto N, Keshavan A, Rajesh A, Kirkish G, Zhang X, et al. Spinal cord atrophy predicts progressive disease in relapsing multiple sclerosis. *Ann Neurol.* 2021;91:268-81. <https://doi.org/10.1002/ana.26281>
31. Hart BA, Luchicchi A, Schenk GJ, Killestein J, Geurts JGG. Multiple sclerosis and drug discovery: A work of translation. *eBioMedicine.* 2021;68:103392. <https://doi.org/10.1016/j.ebiom.2021.103392>
32. Fransen NL, Crusius JBA, Smolders J, et al. Post-mortem multiple sclerosis lesion pathology is influenced by single nucleotide polymorphisms. *Brain Pathol.* 2020;30(1):106-19. <https://doi.org/10.1111/bpa.12760>
33. Correale J, Farez MF. The Role of Astrocytes in Multiple Sclerosis Progression. *Front Neurol.* 2015;6:180. <https://doi.org/10.3389/fneur.2015.00180>
34. Magliozzi R, Hametner S, Facchiano F, et al. Iron homeostasis, complement, and coagulation cascade as CSF signature of cortical lesions in early multiple sclerosis. *Ann Clin Transl Neurol.* 2019;6(11):2150-63. <https://doi.org/10.1002/acn3.50893>
35. Wirth M, Suda KJ, Burns SP, Weaver FM, Collins E, Safdar N, et al. Retrospective Cohort Study of Patient-Reported Urinary Tract Infection Signs and Symptoms Among Individuals With Neurogenic Bladder. *Am J Phys Med Rehabil.* 2023;102(8):663-9. <https://doi.org/10.1097/PHM.0000000000002204>
36. Radecka A, Knyszynska A, Lubkowska A. Assessment of muscle fatigue in multiple sclerosis patients in electromyographic examinations. *Eur J Phys Rehabil Med.* 2023;59(2):152-63. <https://doi.org/10.23736/S1973-9087.23.07667-0>
37. Leodori G, Mancuso M, Maccarrone D, Tartaglia M, Ianniello A, Certo F, et al. Neural bases of motor fatigue in multiple sclerosis: A multimodal approach using neuromuscular assessment and TMS-EEG. *Neurobiol Dis.* 2023;180:106073. <https://doi.org/10.1016/j.nbd.2023.106073>
38. Varga G, Fedorko M, Wasserbauer R, Markusova J, Praksova P, Adedokun V, et al. Urinary tract infections in patients with multiple sclerosis and different methods of bladder evacuation. *Actas Urol Esp (Engl Ed).* 2022;46(10):606-12. <https://doi.org/10.1016/j.acuro.2022.03.006>
39. Rae-Grant AD. Unusual symptoms and syndromes in multiple sclerosis. *Continuum (Minneapolis Minn).* 2013;19(4):992-1006. <https://doi.org/10.1212/01.CON.0000433287.30715.07>

40. McDonald I, Compston A, Edan G, Goodkin D, Hartung HP, Lublin FD, et al. Recommended diagnostic criteria for multiple sclerosis: Guidelines from the International Panel on the Diagnosis of Multiple Sclerosis. *Ann Neurol*. 2001;59:1145-6302. <https://doi.org/10.1002/ana.1032>
41. Thompson AJ, Banwell BL, Barkhof F, et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald Criteria. *Lancet Neurol*. 2018;17(2):162-73. [https://doi.org/10.1016/S1474-4422\(17\)30470-2](https://doi.org/10.1016/S1474-4422(17)30470-2)
42. Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi M, et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. *Ann Neurol*. 2011;69:292-302. <https://doi.org/10.1002/ana.22366>
43. Link H, Huang YM. Oligoclonal bands in multiple sclerosis cerebrospinal fluid: an update on methodology and clinical usefulness. *J Neuroimmunol*. 2006;180:17-28. <https://doi.org/10.1016/j.jneuroim.2006.07.006>
44. Neema M, Stankiewicz J, Arora A, Guss ZD, Bakshi R. MRI in multiple sclerosis: What's inside the toolbox? *Neurotherapeutics*. 2007;4:602-17. <https://doi.org/10.1016/j.nurt.2007.08.001>
45. Teoli D, Rocha Cabrero F, Smith T, Ghassemzadeh S. Lhermitte Sign. *StatPearls*. Treasure Island (FL): StatPearls Publishing; 2023.
46. Sinnecker T, Kuchling J, Dusek P, Dorr J, Niendorf T, Paul F, et al. Ultrahigh field MRI in clinical neuroimmunology: A potential contribution to improved diagnostics and personalised disease management. *EPMA J*. 2015;6:16. <https://doi.org/10.1186/s13167-015-0038-y>
47. Hemond CC, Bakshi R. *Cold Spring Harb Perspect Med*. 2018;8(5):a028969. <https://doi.org/10.1101/cshperspect.a028969>
48. Bielekova B, Martin R. Development of biomarkers in multiple sclerosis. *Brain*. 2004;127:1463-78. <https://doi.org/10.1093/brain/awh176>
49. Sellebjerg F, Bornsen L, Ammitzbøll C, Nielsen JE, Vinther-Jensen T, Hjerminde LE, et al. Defining active progressive multiple sclerosis. *Mult Scler*. 2017;23:1727-35. <https://doi.org/10.1177/1352458517726592>
50. Villar L, Garcia-Barragan N, Espino M, Roldan E, Sadaba M, Gomez-Rial J, et al. Influence of oligoclonal IgM specificity in multiple sclerosis disease course. *Mult Scler*. 2008;14:183-7. <https://doi.org/10.1177/1352458507082046>
51. Becker M, Latache C, Roman E, Debouverie M, Malaplate-Armand C, Guillemin F. No prognostic value of routine cerebrospinal fluid biomarkers in a population-based cohort of 407 multiple sclerosis patients. *BMC Neurol*. 2015;15:79. <https://doi.org/10.1186/s12883-015-0330-4>
52. Villar LM, Sadaba MC, Roldan E, Masjuan J, Gonzalez-Porcu P, Villarrubia N, et al. Intrathecal synthesis of oligoclonal IgM against myelin lipids predicts an aggressive disease course in MS. *J Clin Invest*. 2005;115:187-94. <https://doi.org/10.1172/JCI22833>
53. Alvarez-Cermeno JC, Munoz-Negrete FJ, Costa-Frossard L, Sainz de la Maza S, Villar LM, Rebollo G. Intrathecal lipid-specific oligoclonal IgM synthesis associates with retinal axonal loss in multiple sclerosis. *J Neurol Sci*. 2016;360:41-4. <https://doi.org/10.1016/j.jns.2015.11.030>
54. Thangarajh M, Gomez-Rial J, Hedstrom AK, Hillert J, Alvarez-Cermeno JC, Masterman T, et al. Lipid-specific immunoglobulin M in CSF predicts adverse long-term outcome in multiple sclerosis. *Mult Scler*. 2008;14:1208-13. <https://doi.org/10.1177/1352458508095729>
55. Monreal E, Sainz de la Maza S, Costa-Frossard L, Walo-Delgado P, Zamora J, Fernandez-Velasco JI, et al. Predicting Aggressive Multiple Sclerosis with Intrathecal IgM Synthesis among Patients with a Clinically Isolated Syndrome. *Neurol Neuroimmunol Neuroinflamm*. 2021;8:1047. <https://doi.org/10.1212/NXI.0000000000001047>
56. Walsh P, Kane N, Butler S. The clinical role of evoked potentials. *J Neurol Neurosurg Psychiatry*. 2005;76:ii16-22. <https://doi.org/10.1136/jnnp.2005.068130>
57. Hardmeier M, Leocani L, Fuhr P. A new role for evoked potentials in MS? Repurposing evoked potentials as biomarkers for clinical trials in MS. *Mult Scler*. 2017;23:1309-19. <https://doi.org/10.1177/1352458517707265>
58. Gurtner KM, Shosha E, Bryant SC, Andreghetto BD, Murray DL, Pittock SJ, et al. CSF free light chain identification of demyelinating disease: Comparison with oligoclonal banding and other CSF indexes. *Clin Chem Lab Med*. 2018;56:1071-80. <https://doi.org/10.1515/cclm-2017-0901>
59. Presslauer S, Milosavljevic D, Brucke T, Bayer P, Hubl W. Elevated levels of kappa free light chains in CSF support the diagnosis of multiple sclerosis. *J Neurol*. 2008;255:1508-14. <https://doi.org/10.1007/s00415-008-0954-z>
60. Rinker JR 2nd, Trinkaus K, Cross AH. Elevated CSF free kappa light chains correlate with disability prognosis in multiple sclerosis. *Neurology*. 2006;67:1288-90. <https://doi.org/10.1212/01.wnl.0000238107.31364.21>
61. Villar LM, Espino M, Costa-Frossard L, Muriel A, Jimenez J, Alvarez-Cermeno JC. High levels of cerebrospinal fluid free kappa chains predict conversion to multiple sclerosis. *Clin Chim Acta*. 2012;413:1813-6. <https://doi.org/10.1016/j.cca.2012.07.007>
62. Bonacchi R, Filippi M, Rocca MA. Role of artificial intelligence in MS clinical practice. *Neuroimage Clin*. 2022;35:103065. <https://doi.org/10.1016/j.nicl.2022.103065>
63. Wang SH, Tang C, Sun J, Yang J, Huang C, Phillips

- P, et al. Multiple sclerosis identification by 14-layer convolutional neural network with batch normalization, dropout, and stochastic pooling. *Front Neurosci.* 2018;12:818.
<https://doi.org/10.3389/fnins.2018.00818>
64. Zhang YD, Pan C, Sun J, Tang C. Multiple sclerosis identification by convolutional neural network with dropout and parametric ReLU. *J Comput Sci.* 2018;28:1-10.
<https://doi.org/10.1016/j.jocs.2018.07.003>
65. Eitel F, Soehler E, Bellmann-Strobl J, Brandt AU, Ruprecht K, Giess RM, et al. Uncovering convolutional neural network decisions for diagnosing multiple sclerosis on conventional MRI using layer-wise relevance propagation. *Neuroimage Clin.* 2019;24:102003.
<https://doi.org/10.1016/j.nicl.2019.102003>
66. Lopatina A, Ropele S, Sibgatulin R, Reichenbach JR, Gullmar D. Investigation of deep-learning-driven identification of multiple sclerosis patients based on susceptibility-weighted images using relevance analysis. *Front Neurosci.* 2020;14:609468.
<https://doi.org/10.3389/fnins.2020.609468>
67. Yoo Y, Tang LYW, Brosch T, Li DKB, Kolind S, Vavasour I, et al. Deep learning of joint myelin and T1w MRI features in normal-appearing brain tissue to distinguish between multiple sclerosis patients and healthy controls. *Neuroimage Clin.* 2018;17:169-78.
<https://doi.org/10.1016/j.nicl.2017.10.015>
68. Neeb H, Schenk J. Multivariate prediction of multiple sclerosis using robust quantitative MR-based image metrics. *Z Med Phys.* 2019;29(3):262-71.
<https://doi.org/10.1016/j.zemedi.2018.10.004>
69. Fooladi M, Sharini H, Masjoodi S, Khodamoradi E. A novel classification method using effective neural network and quantitative magnetization transfer imaging of brain white matter in relapsing remitting multiple sclerosis. *J Biomed Phys Eng.* 2018;8(4):409-22.
<https://doi.org/10.31661/jbpe.v8i4Dec.926>
70. Zurita M, Montalba C, Labbe T, Cruz JP, da Dalboni Rocha J, Tejos C, et al. Characterization of relapsing-remitting multiple sclerosis patients using support vector machine classifications of functional and diffusion MRI data. *Neuroimage Clin.* 2018;20:724-30.
<https://doi.org/10.1016/j.nicl.2018.09.002>
71. Sacca V, Sarica A, Novellino F, Barone S, Tallarico T, Filippelli E, et al. Evaluation of machine learning algorithms performance for the prediction of early multiple sclerosis from resting-state fMRI connectivity data. *Brain Imaging Behav.* 2019;13(4):1103-14.
<https://doi.org/10.1007/s11682-018-9926-9>
72. Eshaghi A, Wottschel V, Cortese R, Calabrese M, Sahraian MA, Thompson AJ, et al. Gray matter MRI differentiates neuromyelitis optica from multiple sclerosis using random forest. *Neurology.* 2016;87(23):2463-70.
<https://doi.org/10.1212/WNL.0000000000003395>
73. Hauser SL, Bar-Or A, Cohen JA, Comi G, Correale J, Coyle PK, et al. Ofatumumab versus teriflunomide in multiple sclerosis. *N Engl J Med.* 2020;383(6):546-57.
<https://doi.org/10.1056/NEJMoa1917246>
74. Garrudo FF, Mikael PE, Xia K, Silva JC, Ouyang Y, Chapman CA, Hoffman PR, Yu Y, Han X, Rodrigues CA, Cabral JM. The effect of electrospun scaffolds on the glycosaminoglycan profile of differentiating neural stem cells. *Biochimie.* 2021 Mar 1;182:61-72.
<https://doi.org/10.1016/j.biochi.2021.01.001>
75. McKay CS, Finn MG. Click chemistry in complex mixtures: bioorthogonal bioconjugation. *Chemistry & biology.* 2014 Sep 18;21(9):1075-101.
<https://doi.org/10.1016/j.chembiol.2014.09.002>
76. Pohl AD, Schmidt A, Zhang AH, Maldonado T, Königs C, Scott DW. Engineered regulatory T cells expressing myelin-specific chimeric antigen receptors suppress EAE progression. *Cellular Immunology.* 2020 Dec 1;358:104222.
<https://doi.org/10.1016/j.cellimm.2020.104222>
77. Wallin MT, Culpepper WJ, Campbell JD, Nelson LM, Langer-Gould A, Marrie RA, Cutter GR, Kaye WE, Wagner L, Tremlett H, Buka SL. The prevalence of MS in the United States: a population-based estimate using health claims data. *Neurology.* 2019 Mar 5;92(10):e1029-40.
<https://doi.org/10.1212/WNL.0000000000007035>
78. Galetta SL, Markowitz C, Lee AG. Immunomodulatory agents for the treatment of relapsing multiple sclerosis: a systematic review. *Archives of internal medicine.* 2002 Oct 28;162(19):2161-9.
<https://doi.org/10.1001/archinte.162.19.2161>
79. Pourabdolhossein F, Hamidabadi HG, Bojnordi MN, Rostam SM. Stem cell therapy: A promising therapeutic approach for multiple sclerosis. *Exon Publications.* 2017 Nov 8:85-108.
<https://doi.org/10.15586/codon.multiplesclerosis.2017.ch6>
80. Cohen JA, Comi G, Selmaj KW, Bar-Or A, Arnold DL, Steinman L, Hartung HP, Montalban X, Havrdová EK, Cree BA, Sheffield JK. Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (RADIANCE): a multicentre, randomised, 24-month, phase 3 trial. *The Lancet Neurology.* 2019 Nov 1;18(11):1021-33.
[https://doi.org/10.1016/S1474-4422\(19\)30238-8](https://doi.org/10.1016/S1474-4422(19)30238-8)
81. Miller AE, Wolinsky JS, Kappos L, Comi G, Freedman MS, Olsson TP, Bauer D, Benamor M, Truffinet P, O'Connor PW. Oral teriflunomide for patients with a first clinical episode suggestive of multiple sclerosis (TOPIC): a randomised, double-blind, placebo-controlled, phase 3 trial. *The Lancet Neurology.* 2014 Oct 1;13(10):977-86.
[https://doi.org/10.1016/S1474-4422\(14\)70191-7](https://doi.org/10.1016/S1474-4422(14)70191-7)
82. Cohen JA, Coles AJ, Arnold DL, Confavreux C, Fox EJ, Hartung HP, Havrdova E, Selmaj KW, Weiner

HL, Fisher E, Brinar VV. Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial. *The Lancet*. 2012 Nov 24;380(9856):1819-28.

[https://doi.org/10.1016/S0140-6736\(12\)61769-3](https://doi.org/10.1016/S0140-6736(12)61769-3)

83. Comi G, Kappos L, Selmaj KW, Bar-Or A, Arnold DL, Steinman L, Hartung HP, Montalban X, Havrdová EK, Cree BA, Sheffield JK. Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): a multicentre, randomised, minimum 12-month, phase 3 trial. *The Lancet Neurology*. 2019 Nov 1;18(11):1009-20.

[https://doi.org/10.1016/S1474-4422\(19\)30239-X](https://doi.org/10.1016/S1474-4422(19)30239-X)

84. Mills EA, Mao-Draayer Y. Aging and lymphocyte changes by immunomodulatory therapies impact PML risk in multiple sclerosis patients. *Mult Scler*. 2018;24(8):1014-22.

<https://doi.org/10.1177/1352458518775550>

85. Naismith RT, Wundes A, Ziemssen T, et al. Diroximel Fumarate Demonstrates an Improved Gastrointestinal Tolerability Profile Compared with Dimethyl Fumarate in Patients with Relapsing-Remitting Multiple Sclerosis: Results from the Randomized, Double-Blind, Phase III EVOLVE-MS-2 Study. *CNS Drugs*. 2020;34(2):185-96.

<https://doi.org/10.1007/s40263-020-00700-0>

86. Lassmann H. Pathogenic Mechanisms Associated With Different Clinical Courses of Multiple Sclerosis. *Front Immunol*. 2018;9:3116.

<https://doi.org/10.3389/fimmu.2018.03116>

Copyright: © [2025] Mohamed et al. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<http://creativecommons.org/licenses/by/4.0/>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited

Timeline of Publication

Received Date: 13 May 2025

Revised Date: 20 June 2025

Accepted Date: 28 June 2025

Published Date: 30 June 2025